Posted by on Jan 3, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at the risk of reactivating hepatitis B (HBV) infection in patients with lymphoma treated with obinutuzumab (Gazyva) or rituximab (Rituxan). Researchers found that HBV infection was reactivated in some of these patients but treatment options are available. Some background Lymphoma is a cancer of the immune system....

Read More